A detailed history of First Capital Advisors Group, Llc. transactions in Vertex Pharmaceuticals Inc stock. As of the latest transaction made, First Capital Advisors Group, Llc. holds 748 shares of VRTX stock, worth $337,325. This represents 0.14% of its overall portfolio holdings.

Number of Shares
748
Previous 674 10.98%
Holding current value
$337,325
Previous $212,000 24.06%
% of portfolio
0.14%
Previous 0.14%

Shares

5 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q2 2023

Aug 15, 2023

BUY
$314.42 - $351.91 $23,267 - $26,041
74 Added 10.98%
748 $263,000
Q1 2023

May 15, 2023

BUY
$283.23 - $323.1 $190,897 - $217,769
674 New
674 $212,000
Q3 2022

Nov 14, 2022

BUY
$273.83 - $305.53 $193,050 - $215,398
705 New
705 $204,000
Q2 2018

Jul 30, 2018

SELL
$145.72 - $169.96 $9,326 - $10,877
-64 Closed
0 $0
Q1 2018

Apr 11, 2018

BUY
$151.6 - $177.13 $9,702 - $11,336
64 New
64 $10,000

Others Institutions Holding VRTX

About VERTEX PHARMACEUTICALS INC


  • Ticker VRTX
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Biotechnology
  • Shares Outstandng 256,691,008
  • Market Cap $116B
  • Description
  • Vertex Pharmaceuticals Incorporated, a biotechnology company, engages in developing and commercializing therapies for treating cystic fibrosis. The company markets SYMDEKO/SYMKEVI, ORKAMBI, and KALYDECO to treat patients with cystic fibrosis who have specific mutations in their cystic fibrosis transmembrane conductance regulator gene; and TRIKAF...
More about VRTX
Track This Portfolio

Track First Capital Advisors Group, Llc. Portfolio

Follow First Capital Advisors Group, Llc. and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of First Capital Advisors Group, Llc., based on Form 13F filings with the SEC.

News

Stay updated on First Capital Advisors Group, Llc. with notifications on news.